Skip to main content
Top
Published in: Discover Oncology 1/2024

Open Access 01-12-2024 | Cervical Cancer | Research

A combination of cuproptosis and lncRNAs predicts the prognosis and tumor immune microenvironment in cervical cancer

Authors: Yitong Huang, Chenxiang Pan, Suni Wu, Feng Ye, Lihua Yang

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

Background

Cuproptosis induces proteotoxic stress and eventually leads to cell death. However, the relationship between cuproptosis and lncRNAs in cervical cancer has not been fully elucidated. Therefore, we aim to explore the association among lncRNAs, cuproptosis and clinical features in cervical cancer.

Methods

RNA sequencing, genetic mutations, and clinical data of CESC patients were obtained from TCGA. Cuproptosis-associated genes were gathered. WGCNA was used to cluster important modules, and KEGG, GO, GSEA and GSVA were used to explore functional and pathway enrichment. The association between immune microenvironment and cuproptosis-related lncRNAs was performed by using cibersort algorithm and other platforms, including XCELL, TIMER, QUANTISEQ, MCPCOUNTER and EPIC. Fluorescence quantitative PCR was employed to detect the expression of LINC01833 and LINC02321, and CCK-8 and cell scratch assays were used to assess cell proliferation and migration capabilities after LINCRNA interference.

Results

202 upregulated and 45 downregulated lncRNAs were selected. The survival analysis showed that there was a statistically significant difference in survival rates between the high-risk and low-risk groups. The prognosis of tumour mutation burden and the degree of immune infiltration were differed noticeably between the high-risk and low-risk groups. BHG712, TL-2-105, FR-180204, Masitinib, TAK-715, ODI-027, JW-7-24-2, and OSI-930 had substantially higher IC50 values in the high-risk group. Notably, we found AL360178.1 was associated with RNF44 E3 ubiquitin ligase expression. In cervical cancer cell lines, LINC01833 and LINC02321 displayed significant upregulation. Efficient siRNA transfection led to a decreased expression of LINC01833 and LINC02321. This knockdown significantly hindered both cell proliferation and migration capabilities in cervical cancer cells compared to the negative control.

Conclusion

In conclusion, we constructed five cuprotosis-related lncRNA prognostic models, which may be new tumor therapeutic targets for the prevention and treatment of cervical cancer.
Literature
1.
go back to reference Kuehn B. Reducing cervical cancer deaths. JAMA. 2019;322:198–198.PubMed Kuehn B. Reducing cervical cancer deaths. JAMA. 2019;322:198–198.PubMed
2.
go back to reference Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.PubMedCrossRef Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.PubMedCrossRef
4.
go back to reference Rahangdale L, Mungo C, O’Connor S, Chibwesha CJ, Brewer NT. Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022;379: e070115.PubMedCrossRef Rahangdale L, Mungo C, O’Connor S, Chibwesha CJ, Brewer NT. Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022;379: e070115.PubMedCrossRef
5.
go back to reference Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. The Lancet. 2019;393:169–82.CrossRef Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. The Lancet. 2019;393:169–82.CrossRef
6.
go back to reference Cremer M, Alfaro K, Masch R. Cervical cancer screening in low- and middle-income countries. JAMA. 2021;325:790–790.PubMedCrossRef Cremer M, Alfaro K, Masch R. Cervical cancer screening in low- and middle-income countries. JAMA. 2021;325:790–790.PubMedCrossRef
7.
go back to reference Lucksom PG, Sherpa ML, Pradhan A, Lal S, Gupta C. Advances in HPV screening tests for cervical cancer-A review. J Obstet Gynaecol India. 2022;72:13–8.PubMedCrossRef Lucksom PG, Sherpa ML, Pradhan A, Lal S, Gupta C. Advances in HPV screening tests for cervical cancer-A review. J Obstet Gynaecol India. 2022;72:13–8.PubMedCrossRef
8.
go back to reference Rathod S, Potdar J, Gupta A, Sethi N, Dande A. Empowering women’s Health: insights Into HPV vaccination and the prevention of invasive cervical cancer. Cureus. 2023;15: e49523.PubMedPubMedCentral Rathod S, Potdar J, Gupta A, Sethi N, Dande A. Empowering women’s Health: insights Into HPV vaccination and the prevention of invasive cervical cancer. Cureus. 2023;15: e49523.PubMedPubMedCentral
9.
go back to reference Joseph A, Castedo-Delrieu M, Bloy N, Labaied N, Mondini M, Loi M, et al. Prognostic value of dendritic cells in locally advanced cervical cancer patients. J Clin Oncol. 2020;38:e18016–e18016.CrossRef Joseph A, Castedo-Delrieu M, Bloy N, Labaied N, Mondini M, Loi M, et al. Prognostic value of dendritic cells in locally advanced cervical cancer patients. J Clin Oncol. 2020;38:e18016–e18016.CrossRef
10.
go back to reference Lei J, Arroyo-Mühr LS, Lagheden C, Eklund C, Kleppe SN, Elfström M, et al. Human papillomavirus infection determines prognosis in cervical cancer. J Clin Oncol. 2022;40:1522–8.PubMedCrossRef Lei J, Arroyo-Mühr LS, Lagheden C, Eklund C, Kleppe SN, Elfström M, et al. Human papillomavirus infection determines prognosis in cervical cancer. J Clin Oncol. 2022;40:1522–8.PubMedCrossRef
11.
go back to reference Dueñas-González A, Lizano M, Candelaria M, Cetina L, Arce C, Cervera E. Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer. 2005;4:38.PubMedPubMedCentralCrossRef Dueñas-González A, Lizano M, Candelaria M, Cetina L, Arce C, Cervera E. Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer. 2005;4:38.PubMedPubMedCentralCrossRef
12.
go back to reference Brisson M, Drolet M. Global elimination of cervical cancer as a public health problem. Lancet Oncol. 2019;20:319–21.PubMedCrossRef Brisson M, Drolet M. Global elimination of cervical cancer as a public health problem. Lancet Oncol. 2019;20:319–21.PubMedCrossRef
13.
go back to reference Takekuma M, Matsuzaki S, Matsuo K. Utilization and outcome of systemic chemotherapy for high-risk early-stage cervical cancer. J Clin Oncol. 2021;39:e17521–e17521.CrossRef Takekuma M, Matsuzaki S, Matsuo K. Utilization and outcome of systemic chemotherapy for high-risk early-stage cervical cancer. J Clin Oncol. 2021;39:e17521–e17521.CrossRef
14.
go back to reference Chaudary N, Hill RP, Kelley L, Milosevic MF. Effect of the oral CXCR4 inhibitor X4–136 on tumor control and side effects in cervical cancer treated with radiotherapy and concurrent chemotherapy. J Clin Oncol. 2020;38:e18010–e18010.CrossRef Chaudary N, Hill RP, Kelley L, Milosevic MF. Effect of the oral CXCR4 inhibitor X4–136 on tumor control and side effects in cervical cancer treated with radiotherapy and concurrent chemotherapy. J Clin Oncol. 2020;38:e18010–e18010.CrossRef
15.
go back to reference Symonds R, Davidson S, Chan S, Reed N, McMahon T, Paul J. SCOTCERV: a phase II trial of docetaxel and gemcitabine as second-line chemotherapy in cervical cancer. J Clin Oncol. 2007;25:5548–5548.CrossRef Symonds R, Davidson S, Chan S, Reed N, McMahon T, Paul J. SCOTCERV: a phase II trial of docetaxel and gemcitabine as second-line chemotherapy in cervical cancer. J Clin Oncol. 2007;25:5548–5548.CrossRef
16.
go back to reference Li W, Chang L, Ju Y, Jiang M, Li L, Wang L, et al. Clinical research on radiotherapy at different time for unresectable cervical cancer. J Clin Oncol. 2013;31:e16516–e16516.CrossRef Li W, Chang L, Ju Y, Jiang M, Li L, Wang L, et al. Clinical research on radiotherapy at different time for unresectable cervical cancer. J Clin Oncol. 2013;31:e16516–e16516.CrossRef
17.
go back to reference Grau-Bejar JF, Garcia-Duran C, Garcia-Illescas D, Mirallas O, Oaknin A. Advances in immunotherapy for cervical cancer. Ther Adv Med Oncol. 2023;15:17588359231163836.PubMedPubMedCentralCrossRef Grau-Bejar JF, Garcia-Duran C, Garcia-Illescas D, Mirallas O, Oaknin A. Advances in immunotherapy for cervical cancer. Ther Adv Med Oncol. 2023;15:17588359231163836.PubMedPubMedCentralCrossRef
18.
go back to reference Turinetto M, Valsecchi AA, Tuninetti V, Scotto G, Borella F, Valabrega G. Immunotherapy for cervical cancer: are we ready for prime time? Int J Mol Sci. 2022;23:3559.PubMedPubMedCentralCrossRef Turinetto M, Valsecchi AA, Tuninetti V, Scotto G, Borella F, Valabrega G. Immunotherapy for cervical cancer: are we ready for prime time? Int J Mol Sci. 2022;23:3559.PubMedPubMedCentralCrossRef
23.
24.
go back to reference Cobine PA, Brady DC. Cuproptosis: cellular and molecular mechanisms underlying copper-induced cell death. Mol Cell. 2022;82:1786–7.PubMedCrossRef Cobine PA, Brady DC. Cuproptosis: cellular and molecular mechanisms underlying copper-induced cell death. Mol Cell. 2022;82:1786–7.PubMedCrossRef
25.
go back to reference Wu M, Han Y, Gong X, Wan K, Liu Y, Zhou Y, et al. Novel insight of CircRNAs in cervical cancer: potential biomarkers and therapeutic target. Front Med. 2022;9:759928.CrossRef Wu M, Han Y, Gong X, Wan K, Liu Y, Zhou Y, et al. Novel insight of CircRNAs in cervical cancer: potential biomarkers and therapeutic target. Front Med. 2022;9:759928.CrossRef
26.
go back to reference Endale HT, Mariye YF, Negash HK, Hassen FS, Asrat WB, Mengstie TA, et al. MiRNA in cervical cancer: diagnosis to therapy: systematic review. Heliyon. 2024;10: e24398.PubMedPubMedCentralCrossRef Endale HT, Mariye YF, Negash HK, Hassen FS, Asrat WB, Mengstie TA, et al. MiRNA in cervical cancer: diagnosis to therapy: systematic review. Heliyon. 2024;10: e24398.PubMedPubMedCentralCrossRef
27.
go back to reference Liu J, Shang G. The roles of noncoding RNAs in the development of osteosarcoma stem cells and potential therapeutic targets. Front Cell Dev Biol. 2022;10:773038.PubMedPubMedCentralCrossRef Liu J, Shang G. The roles of noncoding RNAs in the development of osteosarcoma stem cells and potential therapeutic targets. Front Cell Dev Biol. 2022;10:773038.PubMedPubMedCentralCrossRef
29.
go back to reference Xie W, Chu M, Song G, Zuo Z, Han Z, Chen C, et al. Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer. Semin Cancer Biol. 2022;83:303–18.PubMedCrossRef Xie W, Chu M, Song G, Zuo Z, Han Z, Chen C, et al. Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer. Semin Cancer Biol. 2022;83:303–18.PubMedCrossRef
30.
go back to reference Chen X, Liu Y, Liu H, Wang ZW, Zhu X. Unraveling diverse roles of noncoding RNAs in various human papillomavirus negative cancers. Pharmacol Ther. 2022;238:108188.PubMedCrossRef Chen X, Liu Y, Liu H, Wang ZW, Zhu X. Unraveling diverse roles of noncoding RNAs in various human papillomavirus negative cancers. Pharmacol Ther. 2022;238:108188.PubMedCrossRef
31.
32.
go back to reference Jiang W, Xia J, Xie S, Zou R, Pan S, Wang ZW, et al. Long non-coding RNAs as a determinant of cancer drug resistance: towards the overcoming of chemoresistance via modulation of lncRNAs. Drug Resist Updat. 2020;50:100683.PubMedCrossRef Jiang W, Xia J, Xie S, Zou R, Pan S, Wang ZW, et al. Long non-coding RNAs as a determinant of cancer drug resistance: towards the overcoming of chemoresistance via modulation of lncRNAs. Drug Resist Updat. 2020;50:100683.PubMedCrossRef
33.
go back to reference Liao L-M, Zhang F-H, Yao G-J, Ai S-F, Zheng M, Huang L. Role of long noncoding RNA 799 in the metastasis of cervical cancer through upregulation of TBL1XR1 expression. Mol Ther—Nucl Acids. 2018;13:580–9.CrossRef Liao L-M, Zhang F-H, Yao G-J, Ai S-F, Zheng M, Huang L. Role of long noncoding RNA 799 in the metastasis of cervical cancer through upregulation of TBL1XR1 expression. Mol Ther—Nucl Acids. 2018;13:580–9.CrossRef
34.
go back to reference Meza-Sosa KF, Miao R, Navarro F, Zhang Z, Zhang Y, Hu JJ, et al. SPARCLE, a p53-induced lncRNA, controls apoptosis after genotoxic stress by promoting PARP-1 cleavage. Mol Cell. 2022;82:785-802.e710.PubMedPubMedCentralCrossRef Meza-Sosa KF, Miao R, Navarro F, Zhang Z, Zhang Y, Hu JJ, et al. SPARCLE, a p53-induced lncRNA, controls apoptosis after genotoxic stress by promoting PARP-1 cleavage. Mol Cell. 2022;82:785-802.e710.PubMedPubMedCentralCrossRef
35.
go back to reference Wu Q, Ma J, Wei J, Meng W, Wang Y, Shi M. lncRNA SNHG11 promotes gastric cancer progression by activating the Wnt/β-catenin pathway and oncogenic autophagy. Mol Ther. 2021;29:1258–78.PubMedCrossRef Wu Q, Ma J, Wei J, Meng W, Wang Y, Shi M. lncRNA SNHG11 promotes gastric cancer progression by activating the Wnt/β-catenin pathway and oncogenic autophagy. Mol Ther. 2021;29:1258–78.PubMedCrossRef
36.
go back to reference Huang J, Wang J, He H, Huang Z, Wu S, Chen C, et al. Close interactions between lncRNAs, lipid metabolism and ferroptosis in cancer. Int J Biol Sci. 2021;17:4493–513.PubMedPubMedCentralCrossRef Huang J, Wang J, He H, Huang Z, Wu S, Chen C, et al. Close interactions between lncRNAs, lipid metabolism and ferroptosis in cancer. Int J Biol Sci. 2021;17:4493–513.PubMedPubMedCentralCrossRef
37.
go back to reference Yao J, Chen X, Liu X, Li R, Zhou X, Qu Y. Characterization of a ferroptosis and iron-metabolism related lncRNA signature in lung adenocarcinoma. Cancer Cell Int. 2021;21:340.PubMedPubMedCentralCrossRef Yao J, Chen X, Liu X, Li R, Zhou X, Qu Y. Characterization of a ferroptosis and iron-metabolism related lncRNA signature in lung adenocarcinoma. Cancer Cell Int. 2021;21:340.PubMedPubMedCentralCrossRef
38.
go back to reference Li Y, Gao X, Huang Y, Zhu X, Chen Y, Xue L, et al. Tumor microenvironment promotes lymphatic metastasis of cervical cancer: its mechanisms and clinical implications. Front Oncol. 2023;13:1114042.PubMedPubMedCentralCrossRef Li Y, Gao X, Huang Y, Zhu X, Chen Y, Xue L, et al. Tumor microenvironment promotes lymphatic metastasis of cervical cancer: its mechanisms and clinical implications. Front Oncol. 2023;13:1114042.PubMedPubMedCentralCrossRef
39.
go back to reference Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:D587–92.PubMedCrossRef Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:D587–92.PubMedCrossRef
41.
go back to reference Hu X, Xing H, Wang X, Du L, Huang Y, Hao Y, et al. Knockdown of LncRNA SNHG1 suppresses corneal angiogenesis by the regulation of miR-195-5p/VEGF-A. J Ophthalmol. 2021;2021:6646512.PubMedPubMedCentral Hu X, Xing H, Wang X, Du L, Huang Y, Hao Y, et al. Knockdown of LncRNA SNHG1 suppresses corneal angiogenesis by the regulation of miR-195-5p/VEGF-A. J Ophthalmol. 2021;2021:6646512.PubMedPubMedCentral
42.
go back to reference Chen K, Wang Y, Dai X, Luo J, Hu S, Zhou Z, et al. FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degradation. Cell Death Dis. 2024;15:37.PubMedPubMedCentralCrossRef Chen K, Wang Y, Dai X, Luo J, Hu S, Zhou Z, et al. FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degradation. Cell Death Dis. 2024;15:37.PubMedPubMedCentralCrossRef
43.
go back to reference Viveros-Carreño D, Fernandes A, Pareja R. Updates on cervical cancer prevention. Int J Gynecol Cancer. 2023;33:394–402.PubMedCrossRef Viveros-Carreño D, Fernandes A, Pareja R. Updates on cervical cancer prevention. Int J Gynecol Cancer. 2023;33:394–402.PubMedCrossRef
44.
go back to reference Miccò M, Lupinelli M, Mangialardi M, Gui B, Manfredi R. Patterns of recurrent disease in cervical cancer. J Personal Med. 2022;12:755.CrossRef Miccò M, Lupinelli M, Mangialardi M, Gui B, Manfredi R. Patterns of recurrent disease in cervical cancer. J Personal Med. 2022;12:755.CrossRef
45.
go back to reference Wu H, Zhang ZY, Zhang Z, Xiao XY, Gao SL, Lu C, et al. Prediction of bladder cancer outcome by identifying and validating a mutation-derived genomic instability-associated long noncoding RNA (lncRNA) signature. Bioengineered. 2021;12:1725–38.PubMedPubMedCentralCrossRef Wu H, Zhang ZY, Zhang Z, Xiao XY, Gao SL, Lu C, et al. Prediction of bladder cancer outcome by identifying and validating a mutation-derived genomic instability-associated long noncoding RNA (lncRNA) signature. Bioengineered. 2021;12:1725–38.PubMedPubMedCentralCrossRef
46.
go back to reference Yu Y, Ren K. Five long non-coding RNAs establish a prognostic nomogram and construct a competing endogenous RNA network in the progression of non-small cell lung cancer. BMC Cancer. 2021;21:457.PubMedPubMedCentralCrossRef Yu Y, Ren K. Five long non-coding RNAs establish a prognostic nomogram and construct a competing endogenous RNA network in the progression of non-small cell lung cancer. BMC Cancer. 2021;21:457.PubMedPubMedCentralCrossRef
47.
go back to reference Qing L, Gu P, Liu M, Shen J, Liu X, Guang R, et al. Extracellular matrix-related six-lncRNA signature as a novel prognostic biomarker for bladder cancer. Onco Targets Ther. 2020;13:12521–38.PubMedPubMedCentralCrossRef Qing L, Gu P, Liu M, Shen J, Liu X, Guang R, et al. Extracellular matrix-related six-lncRNA signature as a novel prognostic biomarker for bladder cancer. Onco Targets Ther. 2020;13:12521–38.PubMedPubMedCentralCrossRef
48.
go back to reference Zhong W, Qu H, Yao B, Wang D, Qiu J. Analysis of a long non-coding RNA associated signature to predict survival in patients with bladder cancer. Cureus. 2022;14: e24818.PubMedPubMedCentral Zhong W, Qu H, Yao B, Wang D, Qiu J. Analysis of a long non-coding RNA associated signature to predict survival in patients with bladder cancer. Cureus. 2022;14: e24818.PubMedPubMedCentral
49.
go back to reference Attademo L, Tuninetti V, Pisano C, Cecere SC, Di Napoli M, Tambaro R, et al. Immunotherapy in cervix cancer. Cancer Treat Rev. 2020;90:102088.PubMedCrossRef Attademo L, Tuninetti V, Pisano C, Cecere SC, Di Napoli M, Tambaro R, et al. Immunotherapy in cervix cancer. Cancer Treat Rev. 2020;90:102088.PubMedCrossRef
50.
go back to reference Wang Q, Xu Y. Comprehensive analysis of cuproptosis-related lncRNAs model in tumor immune microenvironment and prognostic value of cervical cancer. Front Pharmacol. 2022;13:1065701.PubMedPubMedCentralCrossRef Wang Q, Xu Y. Comprehensive analysis of cuproptosis-related lncRNAs model in tumor immune microenvironment and prognostic value of cervical cancer. Front Pharmacol. 2022;13:1065701.PubMedPubMedCentralCrossRef
51.
go back to reference Liu L, Zheng J, Xia H, Wu Q, Cai X, Ji L, et al. Construction and comprehensive analysis of a curoptosis-related lncRNA signature for predicting prognosis and immune response in cervical cancer. Front Genet. 2023;14:1023613.PubMedPubMedCentralCrossRef Liu L, Zheng J, Xia H, Wu Q, Cai X, Ji L, et al. Construction and comprehensive analysis of a curoptosis-related lncRNA signature for predicting prognosis and immune response in cervical cancer. Front Genet. 2023;14:1023613.PubMedPubMedCentralCrossRef
52.
go back to reference Liu X, Zhou L, Gao M, Dong S, Hu Y, Hu C. Signature of seven cuproptosis-related lncRNAs as a novel biomarker to predict prognosis and therapeutic response in cervical cancer. Front Genet. 2022;13:989646.PubMedPubMedCentralCrossRef Liu X, Zhou L, Gao M, Dong S, Hu Y, Hu C. Signature of seven cuproptosis-related lncRNAs as a novel biomarker to predict prognosis and therapeutic response in cervical cancer. Front Genet. 2022;13:989646.PubMedPubMedCentralCrossRef
54.
go back to reference Liu J, Chen T, Li S, Liu W, Wang P, Shang G. Targeting matrix metalloproteinases by E3 ubiquitin ligases as a way to regulate the tumor microenvironment for cancer therapy. Semin Cancer Biol. 2022;86:259–68.PubMedCrossRef Liu J, Chen T, Li S, Liu W, Wang P, Shang G. Targeting matrix metalloproteinases by E3 ubiquitin ligases as a way to regulate the tumor microenvironment for cancer therapy. Semin Cancer Biol. 2022;86:259–68.PubMedCrossRef
55.
go back to reference Hou B, Chen T, Zhang H, Li J, Wang P, Shang G. The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy. Front Immunol. 2023;14:1123244.PubMedPubMedCentralCrossRef Hou B, Chen T, Zhang H, Li J, Wang P, Shang G. The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy. Front Immunol. 2023;14:1123244.PubMedPubMedCentralCrossRef
56.
go back to reference Liu Y, Xia H, Li M, Chen Y, Zhou W, Chen Y, et al. Overexpressed RING finger 44 correlates with poor prognosis in hepatocellular carcinoma. J Healthc Eng. 2022;2022:3522866. Liu Y, Xia H, Li M, Chen Y, Zhou W, Chen Y, et al. Overexpressed RING finger 44 correlates with poor prognosis in hepatocellular carcinoma. J Healthc Eng. 2022;2022:3522866.
57.
go back to reference Liu X, Zhao T, Yuan Z, Ge S. MIR600HG sponges miR-125a-5p to regulate glycometabolism and cisplatin resistance of oral squamous cell carcinoma cells via mediating RNF44. Cell Death Discov. 2022;8:216.PubMedPubMedCentralCrossRef Liu X, Zhao T, Yuan Z, Ge S. MIR600HG sponges miR-125a-5p to regulate glycometabolism and cisplatin resistance of oral squamous cell carcinoma cells via mediating RNF44. Cell Death Discov. 2022;8:216.PubMedPubMedCentralCrossRef
Metadata
Title
A combination of cuproptosis and lncRNAs predicts the prognosis and tumor immune microenvironment in cervical cancer
Authors
Yitong Huang
Chenxiang Pan
Suni Wu
Feng Ye
Lihua Yang
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-00964-8

Other articles of this Issue 1/2024

Discover Oncology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine